425: BioNTech Q3 2025: Losses Narrow, CureVac Offer Advances

BioNTech SE reports narrower net losses for the nine months ended September 30, 2025, driven by out-licensing revenue, while progressing its public exchange offer for CureVac N.V. shares.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to €831.1 million from €924.8 million in the same period of 2024.
• Net loss for the three months ended September 30, 2025, was €28.7 million, compared to a net profit of €198.1 million in the three months ended September 30, 2024.
• Total revenues for the nine months ended September 30, 2025, increased by 26% to €1,962.5 million from €1,561.1 million in the same period of 2024.
• Total revenues for the three months ended September 30, 2025, increased by 22% to €1,518.9 million from €1,244.8 million in the same period of 2024.
• COVID-19 vaccine revenues decreased by 13% for the nine months to €1,139.6 million and by 23% for the three months to €853.3 million, primarily due to lower dose volumes.
• Out-licensing revenues of €613.0 million were recognized for both the three and nine months ended September 30, 2025, stemming from the global strategic partnership with Bristol-Myers Squibb (BMS) for pumitamig (BNT327/BMS986545), including a $1.5 billion upfront payment.
• Operating loss for the nine months ended September 30, 2025, decreased to €1,082.1 million from €1,462.9 million in the same period of 2024.
• Operating loss for the three months ended September 30, 2025, was €46.9 million, compared to an operating profit of €10.5 million in the same period of 2024.
• Cash and cash equivalents stood at €10,092.9 million as of September 30, 2025, with total cash, cash equivalents, and security investments accumulating to €16,704.9 million.
• The public exchange offer for all outstanding shares of CureVac N.V. commenced on October 22, 2025, with an implied aggregate equity value of approximately $1.25 billion, and is set to expire on December 3, 2025.
• Research and development expenses for the nine months decreased by 3% to €1,599.5 million, while increasing by 3% for the three months to €564.8 million, driven by late-stage oncology trials and impacted by a one-time impairment of BNT323/DB-1303.
• Other operating expenses included €678.5 million ($790.0 million) related to settlement agreements with CureVac N.V. and GSK plc.

Sentiment

Score: 4

Explanation: While BioNTech demonstrated strategic progress with a significant out-licensing deal and advancements in its oncology pipeline, the immediate financial performance for Q3 2025, including a net loss and declining COVID-19 vaccine revenues, is a concern. The substantial legal settlement costs and the forecast of a full-year net loss for 2025 further weigh on the sentiment. The numerous ongoing patent litigations also introduce considerable uncertainty and potential future liabilities.

Positives

• Total revenues increased by 26% for the nine months ended September 30, 2025, to €1,962.5 million, and by 22% for the three months to €1,518.9 million, compared to the prior year periods.
• Significant out-licensing revenue of €613.0 million was recognized from the global strategic partnership with Bristol-Myers Squibb (BMS) for pumitamig (BNT327/BMS986545), including a $1.5 billion upfront payment.
• The net loss for the nine months ended September 30, 2025, narrowed by 10% to €831.1 million from €924.8 million in the prior year period.
• The operating loss for the nine months ended September 30, 2025, narrowed by 26% to €1,082.1 million from €1,462.9 million in the prior year period.
• A strong liquidity position is maintained with cash, cash equivalents, and security investments totaling €16,704.9 million as of September 30, 2025.
• Progress in the oncology pipeline includes the start of late-stage trials for immuno-oncology and antibody-drug conjugate programs.
• Positive topline Phase 3 results were announced for the LP.8.1-adapted COVID-19 vaccine, showing a robust increase in neutralizing antibodies and a consistent safety profile.
• The acquisition of Biotheus expanded the oncology pipeline, provided full global rights to pumitamig, and added R&D and manufacturing capabilities in China.
• The Alnylam lawsuit concluded favorably with a final judgment of noninfringement in BioNTech's favor and a settlement agreement.
• China's National Medical Product Administration (NMPA) granted Breakthrough Therapy Designation for gotistobart for squamous non-small cell lung cancer (sqNSCLC).

Negatives

• A net loss of €28.7 million was reported for the three months ended September 30, 2025, a significant decrease from a net profit of €198.1 million in the same period of 2024.
• An operating loss of €46.9 million was reported for the three months ended September 30, 2025, compared to an operating profit of €10.5 million in the same period of 2024.
• COVID-19 vaccine revenues, a primary revenue driver, decreased by 23% in Q3 2025 and 13% for the nine months, driven by lower dose volumes.
• Other operating expenses increased significantly, mainly due to €678.5 million ($790.0 million) incurred from settlement agreements with GSK/CureVac.
• A one-time impairment loss of €85.4 million was recognized for the product candidate BNT323/DB-1303 due to revised commercial forecast assumptions.
• The finance result decreased by 52% in Q3 2025 and 47% for the nine months, primarily due to lower interest income and negative foreign exchange differences.
• The development program for BNT312/GEN1042 in combination with pembrolizumab and chemotherapy has been discontinued beyond ongoing clinical trials due to strategic evaluation.
• The company confirmed it does not expect to report a positive net income figure for the full financial year 2025.

Risks

• Demand for the COVID-19 vaccine is expected to continue to decrease in the near future, impacting revenues and leading to challenges in production.
• Inability to increase marketing and sales capabilities independently or through third parties may hinder effective commercialization of product candidates and generation of sufficient product sales revenue.
• Government policies, including those related to manufacturing, export controls, or tariffs, and negative public perception regarding vaccines and mRNA-based therapeutics could severely and adversely impact manufacturing and sales.
• Long-term sustainable profitability is difficult to achieve and maintain, being highly dependent on factors such as new virus variants, regional policy changes, and public health measures.
• The ability to use net operating losses (NOLs) and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty, with deferred tax assets of €68.4 million derecognized due to reduced forecasted taxable profits in the U.S.
• Failure to appropriately account for complex terms in collaboration and licensing agreements could require restatement of financial statements, materially affecting financial condition and results of operations.
• The business is dependent on the successful development, regulatory approval, and commercialization of product candidates based on its technology platforms.
• Contingent liabilities exist from numerous intellectual property disputes (including with CureVac, Moderna, Arbutus/Genevant, GlaxoSmithKline, and Promosome), contractual disputes, product-related disputes, and shareholder claims (Ladewig Proceedings), with outcomes remaining substantially uncertain and potential for material adverse effects.
• The company is unable to estimate the range of reasonably possible loss for substantially all contingent liabilities due to significant uncertainties and complexities.

Future Outlook

The company does not expect to report a positive net income figure for the 2025 financial year. Revenues for 2025 are projected to be between €2.6 billion and €2.8 billion, primarily from COVID-19 vaccine commercial sales and a collaboration agreement. Research and development expenses for 2025 are anticipated to be between €2.0 billion and €2.2 billion, with increased investment in late-stage oncology and COVID-19/flu combination vaccine development, offset by portfolio optimization. Sales, general and administrative expenses for 2025 are expected to range from €550.0 million to €650.0 million. Operating investments in property, plant, and equipment and intangible assets for 2025 are forecast to be between €200.0 million and €250.0 million, excluding any investments by CureVac post-acquisition. The variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season has been launched in multiple regions. A biologics license application for BNT323/DB-1303 in second line endometrial cancer is planned for 2026, subject to regulatory feedback.

Management Comments

• "The Company does not expect to report a positive net income figure for the 2025 financial year."
• "Based on the current development of the year 2025, the Company confirms that it does not expect to report a positive net profit / (loss) figure for the year 2025."
• "We continue to view this product candidate [BNT323/DB-1303] as a foundational opportunity to establish our commercial infrastructure, paving the way for future launches."
• "We believe that any such request for amendment [in Ladewig Proceedings] would be meritless and untimely. However, should plaintiffs obtain leave to amend their pleading, we believe that we have strong defenses against the allegations claimed and intend to vigorously defend ourselves in the lawsuit mentioned above."
• "We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of CureVacs claims is ongoing and complex, and we believe the ultimate outcomes remain substantially uncertain."
• "We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Modernas claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain."
• "We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Arbutus and Genevants claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain."
• "The Company believes it has strong defenses against the allegations claimed relative to each of the patents and intends to vigorously defend itself in the lawsuit mentioned above. However, the Companys analysis of GSKs claims is ongoing and complex, and the Company believes the outcome of the suit remains substantially uncertain."
• "We believe we have strong defenses against the allegations claimed relative to the patent and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Promosomes claim is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain."

Industry Context

The filing illustrates BioNTech's strategic pivot away from its heavy reliance on COVID-19 vaccine revenues, which are declining due to changing market dynamics and seasonal effects. The significant out-licensing deal with BMS and the acquisition of Biotheus highlight a strong focus on diversifying into oncology, particularly next-generation immunotherapies like bispecific antibodies and antibody-drug conjugates (ADCs), aligning with broader industry trends in cancer treatment innovation. The numerous ongoing patent litigations underscore the highly competitive and IP-intensive landscape of the biopharmaceutical sector, especially for companies that achieved rapid success with novel technologies like mRNA. The impairment of a product candidate, despite its strategic importance, reflects the inherent commercial and development risks in the biotech industry. The company's emphasis on 'bio-digital transformation' and being 'data-driven' also points to the increasing integration of advanced computational methods and AI/ML in drug discovery and development across the industry.

Management Changes

Legal Proceedings

• Alnylam Proceedings: Concluded with a final judgment of noninfringement in BioNTech's favor and a settlement agreement on August 29, 2025.
• CureVac Proceedings (Germany): EP122 was nullified by the Federal Patent Court (appeal pending, oral hearing July 2026). DE961 and DE974 were cancelled by the German Patent and Trademark Office (appeals pending). EP668 and EP755 were upheld in amended form by the EPO Opposition Division (BioNTech appealed; infringement hearings postponed to January 27, 2026, with GSK intervening). DE130 validity hearing scheduled for December 8, 2025.
• CureVac Proceedings (United States): Resolved by a settlement agreement on August 7, 2025, which also set a framework for resolving patent litigation outside the U.S. (subject to BioNTech's acquisition of CureVac).
• Moderna Proceedings (Germany): EP565 was revoked by the EPO Opposition Division (Moderna appealed, oral hearing January 27, 2026; EPO Boards of Appeal issued preliminary opinion that EP565 is likely invalid). EP949 was upheld in amended form by the EPO Opposition Division (BioNTech appealed, oral hearing September 2026); Dsseldorf Regional Court found infringement (BioNTech and Pfizer appealed).
• Moderna Proceedings (United Kingdom): UK High Court found EP565 invalid and EP949 valid and infringed. UK Appeals Court denied Moderna's appeal for EP565 (finally revoked). UK Court of Appeal upheld EP949 validity (BioNTech applied for permission to appeal to UK Supreme Court).
• Moderna Proceedings (United States): U.S. District Court litigation stayed. PTAB found all challenged claims of U.S. Patent Nos. 10,933,127 and 10,702,600 to be unpatentable and invalid (Moderna appealed).
• Moderna Proceedings (Netherlands, Ireland, Belgium): Multiple lawsuits filed, with cases in Netherlands, Ireland, and Belgium currently stayed pending outcomes of EPO opposition proceedings or joint requests.
• Arbutus and Genevant Proceedings (United States): Lawsuit filed in April 2023 alleging infringement of five patents related to lipid nanoparticle technology. Currently pending.
• GlaxoSmithKline Proceedings (United States, Ireland, Unified Patent Court, United Kingdom): Multiple lawsuits filed in 2024 and 2025 alleging Comirnaty infringement of various patents. All currently pending.
• Promosome Proceedings (Unified Patent Court): Lawsuit filed in January 2025 alleging Comirnaty infringes EP 2 401 365. Oral hearing scheduled for May 2026.
• Ladewig Proceedings (United States): Securities class action complaint dismissed by the U.S. District Court on September 30, 2025. Plaintiffs did not file a notice of appeal by the deadline.

Related Party Transactions

• ATHOS KG and entities controlled by them (related to a beneficial owner of BioNTech shares) provide rental, property management activities, and sell property, plant and equipment. No significant impact on Q3 2025 financials.
• Members of the Management Board and the Supervisory Board are key management personnel. No significant impact on Q3 2025 financials.

Stakeholder Impact

• Shareholders: Potential dilution from the CureVac exchange offer. Financial performance (Q3 net loss, full-year net loss forecast) could impact share price. Ongoing legal disputes create uncertainty. Strategic partnerships and pipeline progress offer long-term value potential.
• Employees: The acquisition of Biotheus added over 300 employees. Pipeline prioritization costs and restructuring due to pipeline prioritization are noted under 'other obligations' in provisions.
• Customers: Decreasing demand for the COVID-19 vaccine impacts product availability and focus. A new variant-adapted vaccine has been launched for the 2025/2026 season.
• Suppliers/CMOs: Obligations from onerous contracts with contract manufacturing organizations (CMOs) due to redundant production capacities are recorded as provisions.
• Creditors: Financial liabilities decreased due to payments made in connection with the settlement of contractual disputes. The company maintains a strong cash position, providing liquidity.

Next Steps

• The public exchange offer for CureVac N.V. shares is set to expire on December 3, 2025.
• An oral hearing for infringement of EP668 and EP755 (CureVac proceedings) is scheduled for January 27, 2026.
• An oral hearing for Moderna's appeal of the EP565 revocation is scheduled for January 27, 2026.
• A biologics license application for BNT323/DB-1303 in second line endometrial cancer is planned for 2026, subject to regulatory feedback.
• An oral hearing for the Promosome lawsuit in the UPC Munich Division is scheduled for May 2026.
• An oral hearing on the appeal of the EP122 nullity action is scheduled for July 2026.
• An oral hearing for BioNTech's appeal of the EPO Opposition Division's decision on EP949 validity is scheduled for September 2026.
• A decision is expected on the EP949 appeal in the Netherlands on or around December 9, 2025.
• An oral hearing regarding the validity of DE130 before the German Patent and Trademark Office is scheduled for December 8, 2025.
• Continue to develop the COVID-19 vaccine, including in combination with flu protection.
• Continue to focus investments in research and development for late-stage development in oncology.

Key Dates

Recommendation

BioNTech's Q3 2025 results present a mixed financial picture. While the company achieved significant revenue growth driven by a major out-licensing deal with BMS and narrowed its nine-month net loss, it reported a net loss for Q3 and forecasts a full-year net loss for 2025. The decline in COVID-19 vaccine revenues is a clear headwind, and substantial legal settlement costs impacted profitability. The robust cash position and progress in the oncology pipeline, including late-stage trials and a strategic acquisition, are positive long-term indicators. However, the numerous ongoing and complex patent litigations introduce considerable uncertainty and potential future liabilities. Given the transition from a COVID-19 revenue peak to a diversified oncology pipeline, coupled with immediate financial headwinds and persistent legal risks, a 'hold' recommendation is appropriate. Investors should closely monitor the progress of the oncology pipeline, the resolution of legal disputes, and the company's ability to achieve sustainable profitability outside of its COVID-19 vaccine business.

Keywords

BioNTech, CureVac, Q3 2025 Earnings, Financial Results, mRNA Vaccine, Oncology Pipeline, Pumitamig, BNT327, Bristol-Myers Squibb, BMS, COVID-19 Vaccine, Out-licensing, Biotechnology, Pharmaceuticals, Clinical Trials, Patent Litigation, Merger Offer, Acquisition, Biotheus, SEC Filing